Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05398367 · ClinicalTrials.gov registry record · NA

Galactagogue Use in Lactating Women With Low Milk Supply

A NA study of Breast Milk Expression, sponsored by Winthrop University.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
1
Study location

NCT05398367: Recruiting NA study of Breast Milk Expression, sponsored by Winthrop University.

NCT05398367 is a NA study of Breast Milk Expression that is actively recruiting participants, run by Winthrop University. The registered enrollment target is 120 participants, above the 95-participant average among 4 other Breast Milk Expression trials with a reported enrollment target (26% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05398367, a NA study of Breast Milk Expression, is actively recruiting participants, sponsored by Winthrop University.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

This study aims to determine whether a 20-day supplement with either Oat Mama Lactation Supplement, moringa, or shatavari has any impact on milk production through an increase in serum prolactin levels when compared to the placebo group. This data will be used to determine if clinical recommendations can be made for the use of the studied supplements in increasing milk supply.

Primary Outcome

Change in breast milk supply will be evaluated using 24-hour breast milk expression volume

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Galactagogue Supplement for Treatment of Low Milk Supply

Study Locations (1)

South Carolina

  • Winthrop University - Rock Hill

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2024-03-05
Est. Completion 2026-06-01
Phase NA
Winthrop University

2 total trials

What NCT05398367 shows while recruiting

NCT05398367 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, above the 95-participant average among 4 other Breast Milk Expression trials with a reported enrollment target (26% higher).

The record links to 1 condition, with Breast Milk Expression appearing as the primary indexed condition, and to 1 intervention - of which Galactagogue Supplement for Treatment of Low Milk Supply is the first listed.

NCT05398367 reports a single indexed study location in South Carolina.

Frequently Asked Questions

What is clinical trial NCT05398367 about?

NCT05398367 is a clinical study titled "Galactagogue Use in Lactating Women With Low Milk Supply". This study aims to determine whether a 20-day supplement with either Oat Mama Lactation Supplement, moringa, or shatavari has any impact on milk production through an increase in serum prolactin levels when compared to the placebo group. This data will be used to determine if clinical recommendation...

What is the current status of trial NCT05398367?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2024-03-05. Estimated completion is 2026-06-01.

What conditions does trial NCT05398367 study?

This clinical trial studies the following conditions: Breast Milk Expression.

What interventions are being tested in trial NCT05398367?

The interventions under investigation include: Galactagogue Supplement for Treatment of Low Milk Supply (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05398367?

This trial is sponsored by Winthrop University, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05398367 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Milk Expression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05398367, the US trial registry maintained by the National Library of Medicine. NCT05398367 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.